Manufacturers publish savings programmes in great detail and list prices almost never. Mounjaro is the exception, though not deliberately: the terms and conditions under its savings card contain two numbers that, together, give the price the card is discounting from.
Every figure below was read from Lilly's Mounjaro savings and coverage page on 2026-09-08, terms and conditions included. This page reports prices and the rules attached to them, not who should take the medicine — that belongs with a prescriber, as our editorial standards explain.
What Lilly publishes
| Situation | Price per month | What the card contributes |
|---|---|---|
| Commercial insurance that covers Mounjaro | as little as $25 | Up to $150 per 1-month fill, $300 per 2 months, $450 per 3 months; $1,950 per year; 13 fills per year |
| Commercial insurance that does not cover Mounjaro | $499 | Up to $647 per month; $8,411 per year |
| Uninsured | LillyDirect, self-pay only | No dollar figure on the page we opened |
| Government beneficiaries | Card not available | Excluded from the commercial programme entirely |
A month here means 28 days and up to four single-dose pens; three months means 84 days and up to twelve.
The list price, from Lilly's own caps
A savings card works by paying part of a bill. Cap what it will pay, publish the price the patient is left with, and the original bill follows.
$499 paid + $647 maximum monthly saving = $1,146 for a 28-day fill.
That would be a suggestive coincidence on its own. The annual figure makes it something firmer. Lilly states a maximum annual saving on that tier of $8,411 and, separately, a limit of 13 prescription fills per calendar year:
$647 × 13 = $8,411. Exactly.
The covered tier behaves identically. Its monthly cap is $150 and its annual cap $1,950, and $150 × 13 = $1,950. Two tiers, four published numbers, one internal logic: the monthly cap is the real parameter and the annual cap is that number times the fill limit.
So $1,146 is the reference price Lilly's own programme is built around for a 28-day supply of Mounjaro. That is our arithmetic on published caps rather than a figure Lilly prints, and the caveat matters — a cap is a ceiling, and a ceiling need not be met. But the annual identity holding exactly, twice, on two independent tiers is difficult to read as coincidence.
For scale: $1,146 for 28 days is thirteen fills of $14,898 across a calendar year, before any programme, insurance or discount. That is the number the whole apparatus of cards and tiers exists to move.
The $25 that is usually not $25
The advertised price on the covered tier is "as little as $25". The card contributes at most $150 per one-month prescription. Those two facts define where the headline stops being true:
- Copay $175 → card pays $150 → patient pays $25. The headline holds.
- Copay $300 → card pays $150 → patient pays $150.
- Copay $500 → card pays $150 → patient pays $350.
The break-even is a $175 copay. Below it the card delivers its headline; above it the card delivers $150 and the headline is decoration. Nothing here is concealed — the caps are printed under the offer — but the two numbers are never presented together, and only one of them appears in the large type.
Worth noting for anyone comparing the two tirzepatide brands: Mounjaro's ceiling is $175 and Zepbound's is $125, because Zepbound's card contributes $100 a month rather than $150. Same molecule, same manufacturer, $50 a month of difference in how far the card reaches. Our Zepbound cost page sets out that side, including a 45-day refill condition attached to Zepbound's cheapest price that has no equivalent in Mounjaro's terms.
A correction to our own coverage
Our GLP-1 cost page, written on 2026-09-05, recorded that no manufacturer self-pay programme for Mounjaro could be found on an open page. That is now out of date in two respects, both established on 2026-09-08: Lilly's page states that Mounjaro is available through LillyDirect on a self-pay basis and offers it to uninsured patients, and the $499 non-covered card tier exists and is precisely specified. What still could not be found is a self-pay dollar figure for LillyDirect. The hub has been updated.
The three-month offer, and why it often is not available
Lilly's page is franker about the limits of its own programme than these pages usually are, and the candour is worth quoting because it explains a common disappointment at the counter. The offer is $25 for up to a three-month prescription. The page then advises the patient to telephone the pharmacy and ask whether it will fill a three-month script, warns that a pharmacy may automatically fill a one-month script instead, and states that whether this is possible "may or may not be possible depending on when your next refill is due or what your insurance or your pharmacy allows", adding that Lilly cannot change insurance or pharmacy policies.
Read plainly: the headline offer depends on two parties who did not make it. A patient who is quoted $25 for three months and receives one month for $25 has not been misled by the card — they have met a pharmacy or plan rule the card cannot override.
What this is a price for
Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule approved for weight management. The clinical and regulatory difference between the two brands, and how tirzepatide compares with semaglutide in the only head-to-head trial, are on our tirzepatide vs semaglutide page.
The pricing difference between them is not clinical. It is a set of decisions about which patients each programme is built to reach, and those decisions are legible in four published caps.
Sources, with dates
- Lilly, Mounjaro savings and coverage, including the savings-card terms and conditions for both the covered and non-covered tiers — read 2026-09-08. Every Mounjaro figure on this page comes from it.
- Lilly, Zepbound savings and insurance options — read 2026-09-08, for the Zepbound caps quoted in the comparison.
Prices in this market changed four times in the twelve months to September 2026. Every figure here carries the date it was read; re-check the manufacturer page before relying on any of them.